Related Experiment Video
Updated: Jan 11, 2026
Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis
Published on: June 24, 2018
Farnesyltransferase inhibitors decrease matrix-vesicle-mediated mineralization in SaOS-2 cells
Tim Bürgel1, Daniel Diehl1,2, Elisabeth-Cosima van Lier1
1Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research, Witten/Herdecke University, Witten, Germany.
Background:
Farnesyltransferase inhibitors (FTIs) were developed for preventing the prenylation of aberrant Ras in human cancer. Furthermore, prenylation is involved in multiple biological processes and plays a putative role in signalling pathways such as the Ras-mitogen-activated-protein kinase (MAPK) pathway. Matrix-vesicle-mediated mineralization (MVM) is the first step in the development of eukaryotic mineralized tissue. In this study, we evaluated the effect of FTIs on MVM in the osteosarcoma cell line SaOS-2 and elucidated the role of farnesylation in this process.
Methods:
SaOS-2 cells were treated with the FTIs Lonafarnib and Tipifarnib. Mineralization was assessed using Alizarin Red S staining. Enzyme assays were conducted to measure alkaline phosphatase (ALP) activity. Western blot analysis and Oxford Nanopore sequencing were performed to evaluate the expression of ALP, collagen type I (COL1A1), and Runt-related transcription factor 2 (RUNX2).
Results:
Inhibition of farnesylation by FTIs resulted in decreased mineralization, as evidenced by reduced Alizarin Red S staining. Additionally, RUNX2 activity was diminished, leading to a reduction in MVM and decreased expression of ALP and COL1A1.
Conclusion:
Our findings demonstrate that FTIs Lonafarnib and Tipifarnib impair MVM, highlighting the essential role of farnesylation in biomineralization.
Insights
Farnesyltransferase inhibitors (FTIs) block farnesylation, a process crucial for matrix-vesicle-mediated mineralization (MVM). This study shows FTIs like Lonafarnib and Tipifarnib inhibit MVM in osteosarcoma cells, impacting bone development.
Area of Science:
- Biochemistry
- Cell Biology
- Biomineralization
Background:
- Farnesyltransferase inhibitors (FTIs) target Ras prenylation in cancer therapy.
- Prenylation influences signaling pathways and biological processes.
- Matrix-vesicle-mediated mineralization (MVM) initiates eukaryotic tissue development.
Purpose of the Study:
- To investigate the impact of FTIs on MVM in SaOS-2 osteosarcoma cells.
- To clarify the role of farnesylation in MVM.
Main Methods:
- SaOS-2 cells were treated with Lonafarnib and Tipifarnib.
- Mineralization was quantified using Alizarin Red S staining.
- Alkaline phosphatase (ALP) activity, COL1A1, and RUNX2 expression were analyzed.
Main Results:
- FTI treatment significantly reduced mineralization.
- RUNX2 activity decreased, impacting MVM.
- Expression of ALP and COL1A1 was diminished.
Conclusions:
- FTIs Lonafarnib and Tipifarnib inhibit MVM.
- Farnesylation is essential for successful biomineralization.
More Related Videos
07:51Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
06:47Isolation of Mesenchymal Stem Cells from Human Alveolar Periosteum and Effects of Vitamin D on Osteogenic Activity of Periosteum-derived Cells
Published on: May 4, 2018
